

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 20 of 24 returned.**☐ 1. Document ID: US 20020187130 A1

L4: Entry 1 of 24

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187130

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020187130 A1

TITLE: Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responses

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kindness, George	Middletown	OH	US	
Schumm, Brooke III	Ellicott City	MD	US	
Guilford, F. Timothy	Palo Alto	CA	US	

US-CL-CURRENT: 424/93.7; 514/8

ABSTRACT:

The invention combines a novel combination with two especially important aspects: first, the invention proposes to simultaneously stimulate response in white blood cells and a patient's tumor cells with a mitogen-challenging compound, preferably a lectin, in the preferred mode the selected lectin being phytohemagglutinin ("PHA"), and second, to generate heat shock protein. A method of treatment is set out. The method of manufacturing proposed utilizes a system calculated to better insure sterility and streamline production of the cytokine modulator. A method of testing in conjunction with the therapy is also claimed utilizing clinical assessment of disease activity, patient performance status, and quality of life questionnaire. Should efficacy of a treatment fall off, particularly because of mutation or adaption, the composition and method may be re- applied. The invention is not limited to humans, but is also applicable to mammals. The composition is usable as a stand-alone composition, but preferably is used in conjunction with standard therapy such as radiation, chemotherapy or surgery, particularly surgical therapy, and in conjunction with the administration of cystine, as later defined, to enhance immune system competency.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 2. Document ID: US 20020182585 A1

L4: Entry 2 of 24

File: PGPB

Dec 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020182585

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020182585 A1

TITLE: Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy

PUBLICATION-DATE: December 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kindness, George	Middletown	OH	US	
Guilford, F. Timothy	Palo Alto	CA	US	
Schumm, Brooke III	Ellicott City	MD	US	

US-CL-CURRENT: 435/4; 424/641, 424/702, 514/458

ABSTRACT:

The invention is for the combination of EDTA, cystine, selenium, Vitamin C, Vitamin E, and zinc for anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal and for the monitoring of the response to therapy with the combination. Methods for use of the components and method for performing the monitoring are included. The combination and method are particularly efficacious for vascular deficiency ailments including atherosclerotic vascular disease, reduction of ischemic cerebral event, complications from surgical procedures including restenosis, neurogenerative disease, and erectile disfunction, and vascular deficiency resulting from etiology of sepsis and chronic infection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 20020169195 A1

L4: Entry 3 of 24

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169195

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020169195 A1

TITLE: Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathione

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kindness, George	Middletown	OH	US	
Schumm, Brooke III	Ellicott City	MD	US	
Guilford, F. Timothy	Palo Alto	CA	US	

US-CL-CURRENT: 514/406; 514/562

ABSTRACT:

The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as "HMG-CoA inhibitor(s)"), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination,

especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. Also contemplated is the addition of lipoic acid and compounds to maintain adequate levels of Selenium, Vitamin C and Vitamin E. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristic of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 4. Document ID: US 20020136763 A1

L4: Entry 4 of 24

File: PGPB

Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020136763
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020136763 A1

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Demopoulos, Harry B.	Scarsdale	NY	US	
Seligman, Myron L.	Pleasantville	NY	US	

US-CL-CURRENT: 424/451; 514/18

ABSTRACT:

A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 5. Document ID: US 20020132781 A1

L4: Entry 5 of 24

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020132781
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020132781 A1

TITLE: Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kindness, George	Middletown	OH	US	
Schumm, Brooke III	Ellicott City	MD	US	
Guilford, F. Timothy	Palo Alto	CA	US	

US-CL-CURRENT: [514/27](#); [514/100](#), [514/406](#), [514/423](#), [514/456](#), [514/460](#), [514/547](#)

ABSTRACT:

The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as "HMG-CoA inhibitor(s)"), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. Also contemplated is the addition of lipoic acid and compounds to maintain adequate levels of Selenium, Vitamin C and Vitamin E. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristic of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KIMC
Draw Desc	Image									

☐ 6. Document ID: US 20020086894 A1

L4: Entry 6 of 24

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086894

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086894 A1

TITLE: Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kindness, George	Middletown	OH	US	
Schumm, Brooke III	Ellicott City	MD	US	
Guilford, F. Timothy	Palo Alto	CA	US	

US-CL-CURRENT: [514/403](#); [514/460](#), [514/548](#), [514/562](#)

ABSTRACT:

The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as "HMG-CoA inhibitor(s)"), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially

prostate cancer. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristic of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 7. Document ID: US 20020068270 A1

L4: Entry 7 of 24

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068270

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020068270 A1

TITLE: Assessment of intracellular cysteine and glutathione concentrations

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Crawford, J. Fred	Houston	TX	US	

US-CL-CURRENT: 435/4; 435/383

ABSTRACT:

The present invention provides a cell culture medium and methods useful for determining levels of intracellular function of glutathione or cysteine, and for providing biochemical analysis of antioxidant function in human lymphocytes. The medium of the present invention comprises: a buffered, serum-free solution containing a carbohydrate selected from the group consisting of glucose and a compound biologically capable of producing glucose in the cells, a biologically usable form of pantothenic acid, choline or a biological usable form of a substance capable of producing choline in the cells, inorganic ions comprising chloride, phosphate, calcium, magnesium, potassium, sodium, and iron in a biologically utilizable form, deionized water, and a mitogen in an amount effective to stimulate the lymphocytes being assayed. In addition to the preceding ingredients, the medium effective for measuring glutathione concentration also contains L-Buthionine-[S.R.]-Sulfoximine. The medium effective for measuring cysteine concentration contains, in addition to the listed ingredients, N-Acetyl-L Cysteine and Cumene Hydroperoxide. The buffered, serum-free solution optimally has a pH from about 6.8 to 7.6, and is characterized by being effective to determine intracellular glutathione or cysteine contraction and to analyze biochemically antioxidant function of the lymphocytes. Also provided is a method of biochemically analyzing cellular antioxidant function and glutathione or cysteine functions comprising the steps of: inoculating the appropriate cell culture medium of the present invention with lymphocytes from said individual; incubating the inoculated cell culture medium; and comparing the response of the lymphocytes with an average response of lymphocytes from a control group of individuals.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 8. Document ID: US 20020002136 A1

L4: Entry 8 of 24

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020002136
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020002136 A1

TITLE: Salts of glutathione

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hebert, Rolland F.	Seattle	WA	US	

US-CL-CURRENT: 514/18; 514/55

ABSTRACT:

Stable salts of glutathione with polycations such as chitosan are described. The salts according to the invention are valuable for use as active constituents in pharmaceutical as well as cosmeceutical compositions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 9. Document ID: US 6534540 B2

L4: Entry 9 of 24

File: USPT

Mar 18, 2003

US-PAT-NO: 6534540
DOCUMENT-IDENTIFIER: US 6534540 B2

TITLE: Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kindness; George	Middletown	OH	45044	
Schumm, III; Brooke	Ellicott City	MD	21042	
Guilford; F. Timothy	Palo Alto	CA	94301	

US-CL-CURRENT: 514/461; 514/473

ABSTRACT:

The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as "HMG-CoA inhibitor(s)"), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristic of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.

11 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMCC
Draw Desc	Image									

☐ 10. Document ID: US 6514955 B1

L4: Entry 10 of 24

File: USPT

Feb 4, 2003

US-PAT-NO: 6514955

DOCUMENT-IDENTIFIER: US 6514955 B1

TITLE: Multi-faceted method to repress reproduction of latent viruses in humans and animals

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Van Dyke; Knox	Morgantown	WV		

US-CL-CURRENT: 514/171; 514/198, 514/369, 514/374, 514/378, 514/561, 514/563

ABSTRACT:

Disclosed are methods for repressing reproduction of latent viruses, such as HIV, in animals by the generally concurrent administration of (1) antioxidants including a glutathione agent; and (2) an NFkB induction inhibitor. Also disclosed are pharmaceutical compositions and kits for use in repressing reproduction of latent viruses such as HIV.

10 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMCC
Draw Desc	Image									

☐ 11. Document ID: US 6423687 B1

L4: Entry 11 of 24

File: USPT

Jul 23, 2002

US-PAT-NO: 6423687

DOCUMENT-IDENTIFIER: US 6423687 B1

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: July 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopolos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Pleasantville	NY		

US-CL-CURRENT: 514/18; 514/21

ABSTRACT:

A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

20 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 12. Document ID: US 6350467 B1

L4: Entry 12 of 24

File: USPT

Feb 26, 2002

US-PAT-NO: 6350467

DOCUMENT-IDENTIFIER: US 6350467 B1

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopoulos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Pleasantville	NY		

US-CL-CURRENT: 424/456; 424/422, 424/434, 424/451, 424/464, 424/484, 514/18, 514/21, 514/824, 514/851, 514/866, 514/879, 514/885, 514/894, 514/912, 514/913, 514/934, 514/944, 514/962, 514/970

ABSTRACT:

A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

62 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 13. Document ID: US 6303295 B1

L4: Entry 13 of 24

File: USPT

Oct 16, 2001

US-PAT-NO: 6303295
DOCUMENT-IDENTIFIER: US 6303295 B1

TITLE: Selenoproteins, coding sequences and methods

DATE-ISSUED: October 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Taylor; Ethan Will	Athens	GA		
Nadimpalli; Ram Gopal	Athens	GA		
Ramanathan; Chandra Sekar	Athens	GA		

US-CL-CURRENT: 435/6; 530/350, 530/400, 536/23.1, 536/23.74

ABSTRACT:

The present disclosure provides a method for the identification of nucleotide sequences which encode selenoproteins. Nucleotide sequences are translated in all potential reading frames, those with a relatively large number of UGA or TGA codons are noted, and frameshift-dependent open reading frames and SECIS elements are identified as associated with selenoprotein coding sequences, especially those within or overlapping known open reading frames. Further provided are selenoprotein coding sequences which are associated with certain viruses (e.g., HIV and Ebola), cancer-related genes and coding sequences related to normal functioning of the immune system.

16 Claims, 65 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawn Desc	Image								

KWIC

☐ 14. Document ID: US 6262019 B1

L4: Entry 14 of 24

File: USPT

Jul 17, 2001

US-PAT-NO: 6262019
DOCUMENT-IDENTIFIER: US 6262019 B1
**** See image for Certificate of Correction ****

TITLE: Method of treatment of glutathione deficient mammals

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keller; Robert H	Weston	FL		
Kirshenbaum; David W	Weston	FL		

US-CL-CURRENT: 514/2; 424/49, 424/535, 424/54, 424/655, 514/12, 514/21, 514/23, 514/251, 514/276, 514/7, 530/365, 530/833

ABSTRACT:

Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductant, and reactant. It can be depleted intracellularly either by forming a direct complex with an electrophilic agent (accomplished investigationaly by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels. The disclosure is also of a unique combination of nutritional supplements including n-acetyl cysteine, vitamin C, l-glucosamine, n-acetyl d-glucosamine, quercitin, sylimarin, Alpha lipoic acid and high protein, low fat whey that are combined to support various bodily systems involved in glutathione synthesis, reutilization and storage; all intended to elevate glutathione concentration in the mammalian cell.

29 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 15. Document ID: US 6204248 B1

L4: Entry 15 of 24

File: USPT

Mar 20, 2001

US-PAT-NO: 6204248

DOCUMENT-IDENTIFIER: US 6204248 B1

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: March 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopoulos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Fairfield	CT		

US-CL-CURRENT: 514/21; 514/18

ABSTRACT:

A method of altering an expression of a gene product in cells or an organism, comprising orally administering glutathione in an effective amount and under such conditions to alter a redox potential in the cells. The gene expression may be sensitive to redox potential through one or more of a process of induction, transcription, translation, post-translational modification, release, and/or through a receptor mediated process. The glutathione is preferably administered as an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach.

14 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 16. Document ID: US 6159500 A

L4: Entry 16 of 24

File: USPT

Dec 12, 2000

US-PAT-NO: 6159500

DOCUMENT-IDENTIFIER: US 6159500 A

**** See image for Certificate of Correction ****

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopoulos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Pleasantville	NY		

US-CL-CURRENT: 424/456; 424/451, 424/452, 424/484, 514/18, 514/474, 514/824, 514/851, 514/866, 514/879, 514/894, 514/912, 514/913, 514/931, 514/934, 514/970

ABSTRACT:

A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

59 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 17. Document ID: US 5846961 A

L4: Entry 17 of 24

File: USPT

Dec 8, 1998

US-PAT-NO: 5846961

DOCUMENT-IDENTIFIER: US 5846961 A

**** See image for Certificate of Correction ****

TITLE: Multi-faceted method to repress reproduction of latent viruses in humans and animals

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Van Dyke; Knox	Morgantown	WV		

US-CL-CURRENT: [514/171](#); [514/198](#), [514/369](#), [514/374](#), [514/378](#), [514/561](#), [514/563](#)

ABSTRACT:

Disclosed are methods for repressing reproduction of latent viruses, such as HIV, in animals by the generally concurrent administration of (1) antioxidants including a glutathione agent; and (2) an NFkB induction inhibitor. Also disclosed are pharmaceutical compositions and kits for use in repressing reproduction of latent viruses such as HIV.

32 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 18. Document ID: US 5843785 A

L4: Entry 18 of 24

File: USPT

Dec 1, 1998

US-PAT-NO: 5843785

DOCUMENT-IDENTIFIER: US 5843785 A

**** See image for Certificate of Correction ****

TITLE: Glutathione deficiency as a prognosis for survival in aids

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Herzenberg; Leonore A.	Stanford	CA		
DeRosa; Stephen C.	Palo Alto	CA		
Herzenberg; Leonard A.	Stanford	CA		
Roederer; Mario	Redwood City	CA		

US-CL-CURRENT: [436/86](#); [436/811](#)

ABSTRACT:

Glutathione levels are determined using a glutathione surrogate in HIV-positive patients to evaluate survival longevity and determine appropriate treatment. Low glutathione levels indicate a need for a glutathione enhancing supplement and a more aggressive therapeutic regimen, as well as diminishing drugs which may result in the reduction of available glutathione.

7 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 19. Document ID: US 5824664 A

L4: Entry 19 of 24

File: USPT

Oct 20, 1998

US-PAT-NO: 5824664

DOCUMENT-IDENTIFIER: US 5824664 A

TITLE: Suppression of HIV expression by organic thiophosphate

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schein; Philip S.	Bryn Mawr	PA		
Kalebic; Thea	Bethesda	MD		

US-CL-CURRENT: 514/143; 514/114, 514/665, 514/75

ABSTRACT:

Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.

24 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K00C
Draw Desc	Image									

☐ 20. Document ID: US 5736565 A

L4: Entry 20 of 24

File: USPT

Apr 7, 1998

US-PAT-NO: 5736565

DOCUMENT-IDENTIFIER: US 5736565 A

TITLE: Therapeutic compounds suitable for the treatment of diseases connected with glutathione deficiency, process for their preparation, and pharmaceutical compositions containing same

DATE-ISSUED: April 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ferrari; Lorenzo	Montecarlo			MC

US-CL-CURRENT: 514/423; 548/537

ABSTRACT:

The present invention is referred to sulphur-acylated derivatives of L-pyroglutamyl-L-cysteine of formula (I) ##STR1## where R is a linear or branched

alkyl containing 1 to 6 carbon atoms, their pharmaceutically acceptable salts, the process for their preparation, and the pharmaceutical compositions containing same. Said derivatives are suitable for the treatment of diseases connected with glutathione deficiency.

37 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

[Generate Collection](#)[Print](#)

Term	Documents
N.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	12591988
NS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	44255
ACETYL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	119676
ACETYLS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	177
CYSTEINE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	41045
CYSTEINES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	5535
(2 AND (N ADJ ACETYL ADJ CYSTEINE)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	24
(L2 AND N ACETYL CYSTEINE).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	24

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 24 of 24 returned.**☐ 21. Document ID: US 5691338 A

L4: Entry 21 of 24

File: USPT

Nov 25, 1997

US-PAT-NO: 5691338

DOCUMENT-IDENTIFIER: US 5691338 A

TITLE: 1,2-dithiole-3 thiones for the treatment of reverse transcriptase-dependent viral infections

DATE-ISSUED: November 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prochaska; Hans J.	New York	NY		
Polisky; Bruce	New York	NY		

US-CL-CURRENT: 514/49; 514/252.01, 514/255.05, 514/263.32, 514/274, 514/441

ABSTRACT:

This invention provides a method of inhibiting the replication of a reverse transcriptase-dependent virus in cells which comprises contacting infected cells with an effective amount of a 1,2-dithiole-3-thione. A composition for inhibiting reverse transcriptase-dependent viral replication of cells comprising an effective amount of a 1,2-dithiole-3-thione and a physiologically acceptable carrier is also provided.

15 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 22. Document ID: US 5686436 A

L4: Entry 22 of 24

File: USPT

Nov 11, 1997

US-PAT-NO: 5686436

DOCUMENT-IDENTIFIER: US 5686436 A

**** See image for Certificate of Correction ****

TITLE: Multi-faceted method to repress reproduction of latent viruses in humans and animals

DATE-ISSUED: November 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Van Dyke; Knox	Morgantown	WV		

US-CL-CURRENT: [514/171](#); [514/198](#), [514/369](#), [514/374](#), [514/378](#), [514/561](#), [514/563](#)

ABSTRACT:

Disclosed are methods for repressing reproduction of latent viruses, such as HIV, in animals by the generally concurrent administration of (1) antioxidants including a glutathione agent; and (2) an NFkB induction inhibitor. Also disclosed are pharmaceutical compositions and kits for use in repressing reproduction of latent viruses such as HIV.

30 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 23. Document ID: US 5607974 A

L4: Entry 23 of 24

File: USPT

Mar 4, 1997

US-PAT-NO: 5607974

DOCUMENT-IDENTIFIER: US 5607974 A

TITLE: Treatment of diseases associated with cysteine deficiency

DATE-ISSUED: March 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dr oge; Wulf	Heidelberg			DE
Herzenberg; Leonard A.	Stanford	CA		
Herzenberg; Leonore A.	Stanford	CA		

US-CL-CURRENT: [514/562](#); [514/49](#)

ABSTRACT:

Patients suffering from a pathological condition resulting in reduced intracellular cysteine levels are treated with a cysteine source capable of being transported to the cellular cytoplasm. Particularly, N-acetyl cysteine is employed in the treatment of AIDS patients.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 24. Document ID: US 5580577 A

L4: Entry 24 of 24

File: USPT

Dec 3, 1996

US-PAT-NO: 5580577

DOCUMENT-IDENTIFIER: US 5580577 A

TITLE: Method of treating the symptoms of human rhinovirus infection

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Herzenberg; Leonard A.	Stanford	CA	94305	
Herzenberg; Leonore A.	Stanford	CA	94305	

US-CL-CURRENT: 424/451; 424/464, 514/562, 514/563, 514/885, 560/16, 562/557

ABSTRACT:

A method of treating viral infection comprises the step of administering to a patient harboring a disease-inducing virus other than HIV-1, the virus being one for which an intracellular thiol deficit causes or exacerbates expression of viral genetic information by transcription, translation or viral replication, such as human rhinovirus, an amount effective to inhibit transcriptional or translational expression of genetic information or replication of the virus, of an N-(C.sub.1-4)-acylcysteine, such as N-acetyl cysteine, or a pharmaceutically acceptable salt thereof. Prevention of disease symptoms and reduction of their severity results from the foregoing treatment. Combination of N-(C.sub.1-4)-acylcysteine or its salt with another antiviral drug or drug for alleviating symptoms of viral infection provides additional therapeutic benefits.

2 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

Generate Collection

Print

Term	Documents
N.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	12591988
NS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	44255
ACETYL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	119676
ACETYLS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	177
CYSTEINE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	41045
CYSTEINES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	5535
(2 AND (N ADJ ACETYL ADJ CYSTEINE)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	24
(L2 AND N ACETYL CYSTEINE).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	24

Display Format:

[Previous Page](#)

[Next Page](#)